Photodynamic therapy composition
AssigneeCase Western Reserve University
InventorJames Basilion
Life of this patent
Estimating the term…
Abstract
A method of treating a PSMA expressing cancer in a subject includes (a) administering to the subject a PSMA-targeted phthalocyanine conjugate compound having the formula (I), (b) detecting the PSMA-targeted phthalocyanine compound bound to and/or complexed with the prostate cancer cells to determine the location and/or distribution of the prostate cancer cells in the subject, (c) surgical resection of the detected cancer, and (d) irradiating the PSMA-targeted phthalocyanine compound at the site of surgical resection, thereby inducing the cytotoxic effects of the phthalocyanine compound on residual prostate cancer cells following surgical resection.
Claims27
A method for treating a PSMA expressing cancer comprising:
- (a) administering systemically to a subject with PSMA expressing cancer a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition comprising a PSMA-targeted phthalocyanine compound having the formula (I):
- wherein X is a PSMA targeting moiety;
- R1, R4, R5, R8, R9, R12, R13, and R16 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl;
- R2, R3, R6, R7, R10, R11, R14, and R15 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, C1-6 acyl, C1-6 alkylcarbonyloxy, C1-6 carbocyclylalkyl, C1-6 aminoalkyl, C1-6 alkylamino, C1-6 thioalkyl, C1-6alkylthio, C1-6hydroxyalkyl, C1-6 alkyloxycarbonyl, C1-6 alkylaminocarbonyl, and C1-6 alkylcarbonylamino;
- and pharmaceutically acceptable salts thereof;
- (b) detecting the PSMA-targeted phthalocyanine compound bound to and/or complexed with the cancer cells to determine the location and/or distribution of the cancer cells in the subject;
- (c) surgically resecting the cancer in the subject, wherein the detected PSMA-targeted phthalocyanine compound bound to and/or complexed with the cancer cells guide surgical resection of the cancer;
- and
- (c) irradiating the PSMA-targeted phthalocyanine compound in the site of surgical resection, thereby inducing the cytotoxic effects of the phthalocyanine compound on residual cancer cells following surgical resection.
A method for treating a prostate cancer comprising:
- (a) administering systemically to a subject with prostate cancer a therapeutically effective amount of a PSMA targeted phthalocyanine compound, the pharmaceutical composition comprising a phthalocyanine compound having the formula (I):
- wherein X is a PSMA targeting moiety;
- R1, R4, R5, R8, R9, R12, R13, and R16 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl;
- R2, R3, R6, R7, R10, R11, R14, and R15 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, C1-6 acyl, C1-6 alkylcarbonyloxy, C1-6 carbocyclylalkyl, C1-6 aminoalkyl, C1-6 alkylamino, C1-6 thioalkyl, C1-6alkylthio, C1-6hydroxyalkyl, C1-6 alkyloxycarbonyl, C1-6 alkylaminocarbonyl, and C1-6 alkylcarbonylamino;
- and pharmaceutically acceptable salts thereof;
- (b) detecting the PSMA-targeted phthalocyanine compound bound to and/or complexed with the prostate cancer cells to determine the location and/or distribution of the prostate cancer cells in the subject;
- (c) surgically resecting the prostate cancer in the subject, wherein the detected PSMA-targeted phthalocyanine compound bound to and/or complexed with the prostate cancer cells guide surgical resection of the prostate cancer;
- and
- (c) irradiating the PSMA-targeted phthalocyanine compound at the site of surgical resection, thereby inducing the cytotoxic effects of the phthalocyanine compound on residual prostate cancer cells following surgical resection.
Dependencies are inferred from the claim text.